Artrya has converted its largest US customer and first SAPPHIRE Study participant into a five-year commercial agreement, while delaying its planned Coronary Flow FDA submission to strengthen clinical evidence. The Salix rollout is gaining traction, but revenue remains early and scan volumes are undisclosed.
- Five-year Huntsville agreement with a minimum value of US$0.5 million
- First SAPPHIRE Study participant converted into a commercial customer
- Tanner Health plaque utilisation increased after reimbursement workflow upgrade
- Coronary Flow 510(k) submission delayed for an additional reader study
- $67.2 million held in cash and term deposits at quarter end
Huntsville becomes Artrya’s first SAPPHIRE commercial conversion
Artrya Limited (ASX:AYA) has produced its clearest commercial proof point yet, converting Huntsville Hospital Health System into a paying customer after the US health network participated in the SAPPHIRE Study. Signed after the September quarter, the five-year agreement carries a minimum value of US$0.5 million for Salix Coronary Anatomy, with additional usage-based fees possible from Salix Coronary Plaque and Salix Coronary Flow if that module is cleared.
The agreement is the same first SAPPHIRE conversion reported earlier, but its scale gives the deal more weight than a routine customer win. Huntsville spans 15 hospitals and 19 heart centres across Alabama and Tennessee, with 58 cardiologists and roughly 60,000 non-invasive cardiology tests a year. Artrya said integration planning will begin with the network’s clinical PACS and IT systems before workflow training and reimbursement pathways are addressed.
Salix utilisation moves from deployment towards recurring revenue
Artrya’s commercial base is also moving beyond installation. At Tanner Health, the company said Salix Coronary Anatomy scan volumes rose as the platform became embedded in clinical workflows, while a pre-authorisation feature introduced in mid-September was followed by a material increase in Salix Coronary Plaque assessments. The higher level of activity continued into October, according to the company, although absolute scan volumes have not been disclosed.
The feature allows clinicians to check whether an insurer’s reimbursement pathway supports plaque assessment before ordering the module. Artrya described the early response as evidence that reimbursement workflow integration may help drive adoption of fee-per-scan products, though the observation is based on an initial period at one health system.
Northeast Georgia Health System deployed Salix Coronary Anatomy at its main campus during the quarter and is progressing the rollout across its remaining sites. Cone Health is also working towards deployment after implementation was slowed by its transition into Kaiser Permanente. Artrya said the commercial emphasis is now shifting from bringing systems live to increasing utilisation across the installed base.
Coronary Flow submission delayed for additional clinical work
The more difficult news sits in Artrya’s technology pipeline. The company had previously described its Salix Coronary Flow 510(k) submission as imminent, with FDA clearance anticipated by the end of 2026. It now says a review of clinical study data identified inconsistencies in expert reader assessments within a clinical sub-study, prompting an additional reader study before filing.
Artrya said the extra study was not requested by the FDA and is intended to strengthen the submission ahead of potential clinical evidence requirements. That decision extends the previously anticipated timetable, leaving both the filing date and clearance timing uncertain. Coronary Flow is intended to add flow assessment to Salix’s existing Anatomy and Plaque modules, with reimbursement available under an existing Category I CPT code if cleared.
Cash runway supports the commercial build-out
The company ended September with $37.2 million in cash and a further $30 million in a six-month term deposit, giving a pro forma total of $67.2 million. Net cash outflows were $6.9 million for the quarter, including $6.824 million used in operating activities. Staff costs rose to $3.6 million as commercial activity and headcount expanded, while the company received only $84,000 from customers during the period.
On the Appendix 4C measure, Artrya reported 5.45 quarters of funding based on cash and cash equivalents alone; including the term deposit, it calculated 9.84 quarters. A further $4.8 million FY2026 research and development rebate claim is expected to be received in early 2027, but remains in process.
The commercial question is now becoming more specific: whether Huntsville can translate a large addressable network into sustained scan volumes and whether Tanner’s plaque utilisation uplift persists beyond its initial implementation period. At the same time, the additional Coronary Flow study adds a regulatory milestone to a business already spending heavily to build its US footprint.
Bottom Line?
Huntsville validates Artrya’s SAPPHIRE-to-commercial model, but the next test is converting network scale and early utilisation gains into material recurring revenue while Coronary Flow evidence work resets the regulatory timetable.
Questions in the middle?
- How quickly will Salix be integrated across Huntsville’s 15-hospital network, and what scan volumes will follow?
- Will Tanner Health’s higher Coronary Plaque utilisation persist once the pre-authorisation workflow is established?
- When will the additional reader study be completed, and how will it affect the timing and evidence package for the FDA submission?